Iadademstat (ORY-1001) is a highly selective LSD1 inhibitor, which mediates LSD1 inhibition and downregulates the expression of ASCL1, thereby reducing the tumorigenesis of SCLC.105 Another selective, oral LSD1 inhibitor (GSK2879552) has also shown antitumor properties in both SCLC cell lines and tumor models.106 Overall, the preclinical studies of LSD1 inhibitors in SCLC suggest that it has the potential to develop epigenetic therapies for SCLC. This evidence concerns the gene ASCL1 and neoplasm.